[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-459951-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-459951-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","om-85-and-respiratory-symptoms-in-korean-chronic-obstructive-pulmonary-disease-a-multicenter-observational-study","OM-85 and Respiratory Symptoms in Korean Chronic Obstructive Pulmonary Disease - A Multicenter Observational Study","","Background: Although OM-85 may lessen respiratory symptoms and reduce acute exacerbations in chronic obstructive pulmonary disease (COPD), overall effectiveness remains incomplete. Methods: A prospective, observational, single-arm study enrolled adults with spirometry-confirmed COPD prescribed OM-85 at four South Korean university hospitals, with 6-month follow-up (3-month treatment, 3-month observation). Symptoms and HRQoL were assessed with modified Medical Research Council, CAT, and SGRQ, recording exacerbations and adverse events. Results and conclusion describe meaningful symptom and HRQoL improvements, especially with higher baseline symptom severity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/om-85-and-respiratory-symptoms-in-korean-chronic-obstructive-pulmonary-disease-a-multicenter-observational-study/459951/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/om-85-and-respiratory-symptoms-in-korean-chronic-obstructive-pulmonary-disease-a-multicenter-observational-study/459951.png","ImageObject",300,407,{"name":42,"@type":43},"Mabel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main purpose of using OM-85 in COPD patients?","Question",{"text":63,"@type":64},"The study aimed to evaluate whether OM-85 could lessen respiratory symptoms and reduce acute exacerbations, while clarifying its overall effectiveness and impact on health-related quality of life.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was symptom and quality of life improvement measured?",{"text":68,"@type":64},"Symptoms and HRQoL were assessed using the modified Medical Research Council scale, the COPD Assessment Test (CAT), and the St. George’s Respiratory Questionnaire (SGRQ), with acute exacerbations and adverse events recorded during follow-up.",{"name":70,"@type":61,"acceptedAnswer":71},"Which patients benefited most from OM-85 treatment?",{"text":72,"@type":64},"Clinically meaningful improvements were especially observed in patients with more severe baseline symptoms, including those with higher baseline CAT scores, showing sustained improvements in CAT and SGRQ scores.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},459951,1791029792,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":124,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},7971474920318,"https://ap-avatar.wpscdn.com/avatar/74000ee537e6b0ca360?x-image-process=image/resize,m_fixed,w_180,h_180&k=1788430171632181674","Original Article  \nOM-85 and Respiratory Symptoms in Korean Chronic Obstructive Pulmonary Disease: A Multicenter Observational Study  \nChang-Seok Yoon1, Tae-Ok Kim1, Hong-Joon Shin1, Hak-Ryul Kim2, Ki-Eun Hwang2, Sung Ho Yoon3, Seoung Ju Park4 and Yong-Soo Kwon1  \n1Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, 2Division of Pulmonary Medicine, Department of Internal Medicine, Wonkwang University School of Medicine, Iksan, 3Department of Pulmonology and Critical Care Medicine, Chosun University Hospital, Gwangju, 4Department of Internal Medicine, Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Republic of Korea  \nAbstract  \nBackground: Although OM-85 may lessen respiratory symptoms and reduce acute exacerbations in chronic obstructive pulmonary disease (COPD), proof of its overall effectiveness remains incomplete.  \nMethods: This prospective, observational, single-arm study was conducted at four university hospitals in South Korea from June 2022 to December 2023. Adults with spirometry-confirmed COPD who were prescribed OM-85 were enrolled, and followed for 6 months (3-months treatment, 3-months observation) . Symptoms and health-related quality of life were assessed using the modified Medical Research Council scale, COPD Assessment Test (CAT), and St. George’s Respiratory Questionnaire (SGRQ) . Acute exacerbations and adverse events were recorded.  \nResults: Of the 323 patients analyzed (mean age 73.3±7 .8 years; 83.9% male), 39.0% had baseline CAT ≥10 . Patients in this group experienced markedly greater and sustained improvements in both CAT and SGRQ scores compared with those with CAT \u003C10 (p for interaction \u003C0 .001 for both), and the magnitude of these changes exceeded the minimal clinically important difference (CAT: −3 .21±3 .85; SGRQ: −10 .42±14 .87 at 6 months), indicating clinically meaningful symptom relief. Among these patients, achieving SGRQ responder status at 6 months was negatively associated with an increased frequency of acute exacerbations (odds ratio, 0.246; 95% confidence interval, 0.050 to 1. 207; p=0 .084), showing a nonsignificant trend. OM-85 was well tolerated, with only mild, reversible drugrelated adverse events.  \nConclusion: OM-85 treatment resulted in meaningful improvements in symptoms and healthrelated quality of life, particularly among patients with more severe baseline symptoms, and was in general well tolerated.  \nKeywords: OM-85; Chronic Obstructive Pulmonary Disease; Symptom; Quality of Life  \n[https://doi.org/10.4046/trd.2025.0105](https://doi.org/10.4046/trd.2025.0105)  \nISSN: 1738-3536(Print)/ 2005-6184(Online) Tuberc Respir Dis 2026;89:55-64  \nCopyright © 2026 The Korean Academy of Tuberculosis and Respiratory Diseases  \nAddress for correspondence Yong-Soo Kwon  \nDepartment of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, 42 Jebong-ro, Dong-gu, Gwangju 61469, Republic of Korea Phone 82-62-220-6575  \nFax 82-62-225-8578  \n[E-mail](E-mail yskwon@jnu.ac.krt)[ yskwon@jnu.ac.krt](E-mail yskwon@jnu.ac.krt)[ ](E-mail yskwon@jnu.ac.krt)[Received](Received Jun. 21)[ Jun. 21](Received Jun. 21), 2025  \nRevised Aug. 14, 2025  \nAccepted Sep. 2, 2025  \nPublished online Sep. 4, 2025  \nIt is identical to the Creative Commons Attribution NonCommercial License ([http://](http://)[ ](http://)[creativecommons.org/licenses/](creativecommons.org/licenses/)[ ](creativecommons.org/licenses/)[by-nc/4.0/](by-nc/4.0/)) .  \nTuberc Respir Dis 2026;89:55-64 [https://e-trd.org/](https://e-trd.org/ 55)[ 55](https://e-trd.org/ 55)  \nCS Yoon et al.  \nIntroduction  \nChronic obstructive pulmonary disease (COPD) is a highly prevalent respiratory disorder that affects an estimated 210 million individuals worldwide1. In Korea, the 2012 Korea National Health and Nutrition Examination Survey reported a prevalence of 15.5% among individuals aged ≥40 years, ","cbCaieo5iqGC3ge3","https://ap.wps.com/l/cbCaieo5iqGC3ge3","pdf",166555,"English","# Abstract\n# Introduction","[{\"question\":\"What was the main purpose of using OM-85 in COPD patients?\",\"answer\":\"The study aimed to evaluate whether OM-85 could lessen respiratory symptoms and reduce acute exacerbations, while clarifying its overall effectiveness and impact on health-related quality of life.\"},{\"question\":\"How was symptom and quality of life improvement measured?\",\"answer\":\"Symptoms and HRQoL were assessed using the modified Medical Research Council scale, the COPD Assessment Test (CAT), and the St. George’s Respiratory Questionnaire (SGRQ), with acute exacerbations and adverse events recorded during follow-up.\"},{\"question\":\"Which patients benefited most from OM-85 treatment?\",\"answer\":\"Clinically meaningful improvements were especially observed in patients with more severe baseline symptoms, including those with higher baseline CAT scores, showing sustained improvements in CAT and SGRQ scores.\"}]","OM-85 and Respiratory Symptoms in Korean Chronic Obstructive Pulmonary Disease - A Multicenter Observational Study | PDF",1790757334,25]